Community protocol · MOTS-c
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: MOTS-c (Human) · Mitochondrial open reading frame peptide
Sources checked: 27 August 2026
This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Quick context
Is studied for cellular energy metabolism, insulin sensitivity, obesity and bone biology.
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amounts, timing and cycles
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: preclinical.
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community sourceReconstitution and U-100 conversion
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
MOTS-c is classified as “Mitochondrial-derived 16-amino-acid peptide”. Is studied for cellular energy metabolism, insulin sensitivity, obesity and bone biology. This describes the investigated pathway but does not validate a community use, amount, route or combination.
Researchers study how a peptide interacts with the cell's power plants, the mitochondria, and affects their energy production. Measures include oxygen consumption and energy turnover in cell models.
Researchers study how cells produce and use energy, particularly through the mitochondria, similar to measuring how efficiently an engine burns fuel. Typical measures include oxygen consumption and energy output in cell models.
Researchers study how a substance changes blood sugar levels and feelings of hunger over the course of a day, similar to tracking how full someone feels after different meals. Typical measures include blood glucose readings and questionnaires about hunger and food intake.
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
Users compare self-assembled combinations of peptides aimed at influencing ageing processes or energy levels, often based on blood tests or subjective wellbeing scales. Personal self-experiments and marketing promises do not replace controlled long-term human studies.
Subjectively perceived increases in energy after using mitochondrial peptides or vitamin injections are reported, often based on personal daily-energy ratings. Such impressions are strongly influenced by placebo effects.
Combinations of growth-axis, mitochondrial, and skin peptides are compared here with the goal of influencing visible or felt signs of ageing, often documented personally over years. Anecdotes and vendor advertising about slowed ageing are not scientific proof.
Adverse effects and risk boundaries
Exclusion groups and professional assessment
Monitoring and laboratory markers
Evidence boundary
Research is mostly preclinical; statements about humans remain provisional.
Published evidence
Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.
MOTS-c is encoded by mitochondrial DNA, while elamipretide is a synthetic, mitochondria-binding tetrapeptide.
Storage and stability
Troubleshooting and error sources
Regulatory status and WADA
No FDA- or EMA-approved medicinal product; efficacy and safety are not established.
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
Frequently asked questions
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
